Epic launched a prescription marketplace with Amazon Pharmacy, Mark Cuban Cost Plus Drugs, Costco & Eli Lilly, letting ...
Pfizer halts a Phase 2 ITP trial, Lycia targets a $227M IPO, Jemperli wins rectal cancer approval, plus news on AstraZeneca, ...
Rapport’s RAP-219, licensed from J&J, hits Phase 2 bipolar mania goal, with registrational trials planned for 2H 2027.
A Massachusetts jury awards former Whitehead scientist David Sabatini $6M in his defamation suit against his accuser, who ...
Astellas partners with AI Proteins, paying up to $400M, to develop miniprotein therapies using AI. CEO Chris Bahl targets ...
Merck KGaA agrees to buy Silence Therapeutics for $1.3B, adding siRNA drug divesiran, which is headed to Phase 3 in polycythemia vera.
ScionxBio signs first deal with Sanofi to screen mRNA candidates via its TERA platform. CEO Adi Gilboa-Geffen declined to ...
At the three-month point, 30.2% of patients treated with ABBV-466 met the primary endpoint of endoscopic remission.
TriGemX Bio, formerly Kallyope, will go public via a $600M SPAC with TCGX, getting $246M to push its Phase 3 migraine drug ...
The most common side effects seen with ZL-1310 plus Tecentriq in the study were anemia (42.2%), nausea (26.7%), ...
Gilead’s oral α4β7 drug emvistegrast posts 31% UC remission in Ph2 SWIFT, topping Entyvio cross-trial; Phase 3 set for 2027.
A healthcare asset and royalties holding company is bringing a long-acting oral medicine approach back to life, resurrecting a drug delivery platform that had accumulated more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results